Page last updated: 2024-11-07

11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid: RN given refers to cpd without isomeric designation; a major acidic metabolite of tetrahydrocannabinol in human urine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44814488
CHEBI ID183960
SCHEMBL ID15082798
MeSH IDM0066987

Synonyms (12)

Synonym
114028-39-6
CHEBI:183960
(6as,10as)-1-hydroxy-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid
SCHEMBL15082798
104874-50-2
DTXSID90660713
(6as,10as)-1-hydroxy-6,6-dimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromene-9-carboxylic acid
(+/-)-11-nor-9-carboxy-delta9-thc (crm)
(+)-11-nor-delta-9-thc carboxylic acid, 1mg/ml in methanol
(+)-11-nor-delta-9-thc carboxylic acid, 0.1mg/ml in methanol
(+)-11-nor-delta-9-thc carboxylic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The purpose of this work was to link an indoor air quality model (IAQ) with a pharmacokinetic (PK) model to predict a passive marijuana smoker's resultant concentration of the major urinary metabolite THCA."( An indoor air quality-pharmacokinetic simulation of passive inhalation of marijuana smoke and the resultant buildup of 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid in urine.
Giardino, NJ, 1997
)
0.3
"05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67."( Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
George, MP; Gustafson, RA; Huestis, MA; Kim, I; Klette, KL; Levine, B; Moolchan, ET; Stout, PR, 2004
)
0.32
"After cannabis consumption there is only limited knowledge about the pharmacokinetic (PK) and metabolic properties of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC), which is formed by oxidative breakdown from Delta(9)-tetrahydrocannabinol (THC)."( Pharmacokinetics of 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects.
Aderjan, R; Dietz, L; Glaz-Sandberg, A; Mikus, G; Nguyen, H; Oberwittler, H, 2007
)
0.34
" No plasma pharmacokinetic data after repeated oral THC administration are available."( Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
Darwin, WD; Goodwin, RS; Gorelick, DA; Huestis, MA; Karschner, EL; Kelly, DL; Lowe, RH; Schwilke, EW; Schwope, DM, 2009
)
0.35
" There are indications that CBD modulates THC's effects, but it is unclear if this is due to a pharmacokinetic and/or pharmacodynamic interaction."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37
"These data suggest that CBD modulation of THC's effects is not due to a pharmacokinetic interaction at these therapeutic doses."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
"A simple, rapid and highly sensitive method for the analysis of THC-COOH in urine, using automated on-line solid-phase extraction (SPE) combined with liquid chromatography (LC)-mass spectrometry (MS/MS), is developed and fully validated according to international guidelines."( On-line solid-phase extraction combined with liquid chromatography-tandem mass spectrometry for high throughput analysis of 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in urine.
De Boeck, G; Fernández, Mdel M; López-Rivadulla, M; Samyn, N; Wille, SM; Wood, M, 2009
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Relative bioavailability was calculated to determine the relative rate and extent of THC absorption; 5 and 15 mg oral THC bioavailability was 92."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" Simultaneous blood samples were obtained from a maternal uterine vein and an intraplacental artery at 0, 3, 15, 30, 45, 60, 90, 120, and 180 min after dosing using an intraplacental cannulation technique."( Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey.
Bailey, JR; Cunny, HC; Paule, MG; Slikker, W, 1987
)
0.27
"8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session."( Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration.
George, MP; Gustafson, RA; Huestis, MA; Kim, I; Klette, KL; Levine, B; Moolchan, ET; Stout, PR, 2004
)
0.32
" There was a 10-day washout period between each dosing regimen."( Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.
Barnes, A; Elsohly, M; Gustafson, RA; Huestis, MA; Nebro, W; Smith, ML, 2006
)
0.33
" Plasma specimens were collected during and after each dosing condition."( Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Barnes, A; Goodwin, RS; Gustafson, RA; Huestis, MA; Moolchan, ET; Nebro, W, 2006
)
0.33
" Although preliminary in nature, the actual urinary elimination half-life of THCCOOH appears to be significantly shorter than its apparent or terminal half-life reported from single or multiple dosing of delta-9-tetrahydrocannabinol (THC)."( The urinary disposition of intravenously administered 11-nor-9-carboxy-delta-9-tetrahydrocannabinol in humans.
Aderjan, R; Dietz, L; Glaz-Sandberg, A; Mikus, G; Nguyen, H; Skopp, G, 2007
)
0.34
"Nine cannabis smokers completed all 5 dosing sessions."( Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Darwin, WD; Goodwin, RS; Huestis, MA; Karschner, EL; Wright, S, 2011
)
0.37
" Finally, a screening level risk assessment that combines the measured environmental concentrations (MECs) with dose-response data to estimate Hazard Quotients (HQs) for the compounds studied is also presented."( Drugs of abuse and benzodiazepines in the Madrid Region (Central Spain): seasonal variation in river waters, occurrence in tap water and potential environmental and human risk.
Barceló, D; González-Alonso, S; López de Alda, M; Mastroianni, N; Mendoza, A; Rodríguez-Gil, JL; Valcárcel, Y, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-benzopyran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (238)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (12.18)18.7374
1990's29 (12.18)18.2507
2000's68 (28.57)29.6817
2010's105 (44.12)24.3611
2020's7 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (8.88%)5.53%
Reviews7 (2.30%)6.00%
Case Studies10 (3.29%)4.05%
Observational1 (0.33%)0.25%
Other259 (85.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]